Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: Guidance from the British Committee for Standards in Haematology

被引：135
作者：
Baglin, Trevor [1 ]
Keeling, David [2 ]
Kitchen, Steve [3 ]
机构：
[1] Addenbrookes Hosp, Cambridge, England
[2] Oxford Univ Hosp, Oxford, England
[3] Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2012年 / 159卷 / 04期
关键词：
anticoagulants; anticoagulation; laboratory haematology; THROMBIN INHIBITOR DABIGATRAN; ASSAYS;
D O I：
10.1111/bjh.12052
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：427 / 429
页数：3
相关论文
共 9 条
[1]   Rivaroxaban: Quantification by anti-FXa assay and influence on coagulation tests A study in 9 Swiss laboratories [J].
Asmis, L. M. ;
Alberio, L. ;
Angelillo-Scherrer, A. ;
Korte, W. ;
Mendez, A. ;
Reber, G. ;
Seifert, B. ;
Stricker, H. ;
Tsakiris, D. A. ;
Wuillemin, W. A. .
THROMBOSIS RESEARCH, 2012, 129 (04) :492-498
[2]   Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: Two observational studies in patients undergoing total hip or total knee replacement [J].
Freyburger, Genevieve ;
Macouillard, Gerard ;
Labrouche, Sylvie ;
Sztark, Francois .
THROMBOSIS RESEARCH, 2011, 127 (05) :457-465
[3]   Effects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays [J].
Hillarp, A. ;
Baghaei, F. ;
Blixter, I. Fagerberg ;
Gustafsson, K. M. ;
Stigendal, L. ;
Sten-Linder, M. ;
Strandberg, K. ;
Lindahl, T. L. .
JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 (01) :133-139
[4]   Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays [J].
Lindahl, Tomas L. ;
Baghaei, Fariba ;
Blixter, Inger Fagerberg ;
Gustafsson, Kerstin M. ;
Stigendal, Lennart ;
Sten-Linder, Margareta ;
Strandberg, Karin ;
Hillarp, Andreas .
THROMBOSIS AND HAEMOSTASIS, 2011, 105 (02) :371-378
[5]   Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls [J].
Samama, Meyer Michel ;
Contant, Genevieve ;
Spiro, Theodore E. ;
Perzborn, Elisabeth ;
Guinet, Celine ;
Gourmelin, Yves ;
Le Flem, Lena ;
Rohde, Gabriele ;
Martinoli, Jean Luc .
THROMBOSIS AND HAEMOSTASIS, 2012, 107 (02) :379-387
[6]   Assessment of laboratory assays to measure rivaroxaban - an oral, direct factor Xa inhibitor [J].
Samama, Meyer Michel ;
Martinoli, Jean-Luc ;
LeFlem, Lena ;
Guinet, Celine ;
Plu-Bureau, Genevieve ;
Depasse, Francois ;
Perzborn, Elisabeth .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (04) :815-825
[7]   Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran [J].
Stangier, Joachim ;
Feuring, Martin .
BLOOD COAGULATION & FIBRINOLYSIS, 2012, 23 (02) :138-143
[8]   Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: Interpretation of coagulation assays and reversal of anticoagulant activity [J].
van Ryn, Joanne ;
Stangier, Joachim ;
Haertter, Sebastian ;
Liesenfeld, Karl-Heinz ;
Wienen, Wolfgang ;
Feuring, Martin ;
Clemens, Andreas .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (06) :1116-1127
[9]   In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate [J].
Wienen, Wolfgang ;
Stassen, Jean-Marie ;
Priepke, Henning ;
Ries, Uwe Joerg ;
Hauel, Norbert .
THROMBOSIS AND HAEMOSTASIS, 2007, 98 (01) :155-162
1